Nick DeAngelis

Nick’s experience includes representing:

• Pluto Capital, Inc. in its sale to Robinhood Markets, Inc. Pluto Capital, Inc. is an artificial intelligence (AI) powered investment research platform that delivers highly-customized investment strategies based on customer needs and financial goals. 
• RenaissanceRe Holdings Ltd. in a US$1.39 billion common stock offering (inclusive of the exercise of the green shoe) led by Morgan Stanley and Goldman Sachs.
• RenaissanceRe Holdings Ltd. in its US$2.985 billion acquisition of American International Group Inc.’s treaty reinsurance business, which includes Validus Reinsurance Ltd. and its consolidated subsidiaries, AlphaCat Managers Ltd. and its managed funds, and all renewal rights to the Assumed Reinsurance Treaty Unit of Talbot Treaty.
• Atia Vision Inc. in its Series E financing led by Cormorant Asset Management with participation by The Capital Partnership, PA MedTech VC Fund, AMED Ventures, and Shifamed Angel investors.
• Specialty Dental Brands, a dental support organization, in connection with an investment by TSG Consumer Partners, a private equity firm.
• American Airlines in its agreement to purchase up to 20 Boom Supersonic Overture aircraft, with an option for an additional 40.
• American Airlines in its investment in ZeroAvia, a leader in hydrogen-electric, zero-emission aviation.
• The Arnold Companies, in the sale of its TAC Air division to Signature Aviation, the world’s largest network of fixed-base operators.
• EnterpriseDB, in its majority growth investment from Bain Capital Private Equity.
• Callodine Group in its 13e-3 take-private acquisition of investment-management firm Manning & Napier (NYSE: MN).
• IO Biotech, a clinical-stage biopharmaceutical company, on its US$115.1 million initial public offering.
• Argo Blockchain, a global leader in cryptocurrency mining, on its Nasdaq IPO.
• Tempest Therapeutics, a privately held, clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, in connection with its merger with Millendo Therapeutics.
• Regal Beloit Corporation in its US$9.1 billion combination with the Process & Motion Control (PMC) Business of Rexnord Corporation.
• NuVera Medical, Inc., a medical technology company, in connection with its acquisition by Biosense Webster, a wholly owned subsidiary of Johnson & Johnson.
• Cambium Networks Corporation in its secondary public offering of 2.5 million ordinary shares sold by an affiliate of Vector Capital at US$28.00 per share.
• Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, on its $72 million initial public offering.
• Outset Medical, a medical technology company, on its $278 million initial public offering, its $212 million secondary public offering, and its $365.8 million follow-on offering.
• Kalderos, Inc., a SaaS drug discount management platform company, in its $28 million Series B funding from Bain Capital Ventures and Mercato Partners.
• Salesforce in its $1.33 billion acquisition of Vlocity, Inc.
• GIC Pte. Ltd. in its investment in Apeel Sciences, an innovative food waste reduction company.
• Audio Up Inc., in connection with the sale of Series A Preferred Stock to a group of investors led by Metro-Goldwyn-Mayer Studios (MGM) Inc.
• Shape Security, Inc. in its acquisition by F5 Networks, Inc. for $1 billion.
• Splunk Inc. on its acquisition of cloud monitoring leader SignalFX for $1.05 billion in cash and stock.
• The RealReal in its $345 million initial public offering.
• GlaxoSmithKline in its collaboration with and equity investment in Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer patients.
• Varian Medical’s further expansion into interventional oncology through its acquisitions of Endocare (cryoablation and microwave ablation); Alicon (embolic therapy); and the microsphere and bland embolic bead products of Boston Scientific.
• Capricor Therapeutics (NASDAQ: CAPR) in connection with equity financing transactions.
• Dicerna Pharmaceuticals in connection with PIPE and SEC-registered transactions, as well as ongoing reporting obligations.
• Centrify Corporation in connection with a majority investment by an affiliate of Thoma Bravo.
• Pliant Therapeutics, Inc. in connection with its Series B financing.
• Pandora Media in its $145 million acquisition of AdsWizz.
• Tricida, Inc. in its US$256 million initial public offering its US$57.5 million Series D Financing.
• Corel in its acquisition of ClearSlide.
• CounterPoint Capital Partners in connection with its acquisition of Falcon Transport Co.

Nick is part of a team working alongside pro bono partner Public Counsel that sought a preliminary injunction requiring the government to provide mental health services to a putative class of immigrant families separated upon entry into the United States. On November 6, 2019, in a groundbreaking 50-page order, Judge Kronstadt of the U.S. District Court for the Central District of California granted a preliminary injunction and certified the class, requiring mental health screenings and treatment to help separated family members begin to address the severe and ongoing trauma associated with family separation. Public Counsel honored the team with its 2019 "Pro Bono" award in recognition of Sidley’s efforts on this matter.  

Nick has also represented a variety of other pro bono clients, including the board of directors of a religious school, employees converting their employer into a worker-owned cooperative, and a nonprofit entity providing financing to early stage fintech companies catering to underserved consumers.